Trial Profile
Immunotherapy Followed By EGFR Inhibitor In Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin: Tackling Primary And Secondary Resistance
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms I-Tackle
- 07 Jun 2022 Status changed from not yet recruiting to recruiting as per results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 18 Sep 2018 New trial record